免疫治疗新 ROR:通过单克隆抗体和 CAR NK 细胞靶向 ROR1 近端结构域治疗乳腺癌
A new immunotherapy ROR: Proximal ROR1 domain targeting breast cancer via monoclonal antibodies and CAR NK cells.
ALL SOURCES
A new immunotherapy ROR: Proximal ROR1 domain targeting breast cancer via monoclonal antibodies and CAR NK cells.
Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.
我们的结果表明,分泌细胞因子的溶瘤病毒联合 CAR-NK 细胞是一种治疗高危 NB 的新型有效免疫治疗方法。
Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.
在体内,与单用 anti-ROR1 CAR exPBNK 相比,anti-ROR1 CAR exPBNK 联合 N-803 显著(p < 0.05)提高了人 ROR1⁺ NB 异种移植 NSG 小鼠的生存率。
NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor control.
我们的数据提示,将 NKTR-255 与 CAR-T 疗法联合,是增强 CAR-T 与内源性抗肿瘤免疫、从而促进对侵袭性肿瘤协同控制的一种有前景的策略。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。